Inside Lyme Podcast with Dr. Daniel Cameron

👉 Have you faced delays in Lyme disease treatment? Comment below. Physician reluctance in Lyme disease treatment often stems from liability concerns, conflicting guidelines, limited training, and insurance pressures. While hesitation may protect doctors professionally, it can leave patients untreated, leading to infection spread, long-term complications, and emotional trauma. The risks of treatment — side effects, gut imbalance, or temporary Herxheimer reactions — are usually short-term and manageable, while the risks of inaction include permanent neurologic damage, arthritis, cardiac issues, and even death. The path forward lies in shared decision-making, individualized care, and supporting physicians so they feel safe providing thoughtful, evidence-based treatment. Ultimately, patient welfare must come before professional hesitation. #LymeDisease #LymeWarrior #ChronicLyme #LymeAwareness #PatientStories

👉 Have you faced delays in Lyme disease treatment? Comment below. Physician reluctance in Lyme disease treatment often stems from liability concerns, conflicting guidelines, limited training, and insurance pressures. While hesitation may protect doctors professionally, it can leave patients untreated, leading to infection spread, long-term complications, and emotional trauma. The risks of treatment — side effects, gut imbalance, or temporary Herxheimer reactions — are usually short-term and manageable, while the risks of inaction include permanent neurologic damage, arthritis, cardiac issues, and even death. The path forward lies in shared decision-making, individualized care, and supporting physicians so they feel safe providing thoughtful, evidence-based treatment. Ultimately, patient welfare must come before professional hesitation. #LymeDisease #LymeWarrior #ChronicLyme #LymeAwareness #PatientStories

Have you had symptoms return after stopping Lyme treatment? Share your story below. Your experience may help someone else navigating the same difficult decision. Summary One of the most frequent questions in Lyme care is: “If I feel better, should I stop treatment?” The answer is complicated. While no one wants to stay on antibiotics longer than necessary, stopping too soon often leads to relapse. Lyme disease is not a typical infection. Borrelia burgdorferi can persist by hiding in tissues, forming biofilms, and shifting into alternate forms. When treatment ends prematurely, surviving bacteria may re-emerge, and symptoms such as brain fog, joint pain, fatigue, or neuropathy often return. Co-infections like Babesia or Bartonella add another layer, sometimes becoming more obvious once Lyme therapy is withdrawn. Guidelines remain divided. IDSA discourages extended therapy, while ILADS—where I helped author the 2004 and 2014 guidelines—supports individualized, carefully monitored treatment when patients remain ill. The key is shared decision-making, weighing risks and benefits, and avoiding a one-size-fits-all approach. The goal is not indefinite treatment, but the minimum effective therapy that allows patients to heal and reclaim their lives. The takeaway is simple: stopping Lyme treatment too soon often means starting over. Recovery is about staying better tomorrow—not just feeling better today.

Treating Lyme disease in elderly patients is one of the most complex challenges I see in my practice. Unlike younger adults, older patients often live with multiple health conditions. They may be taking many medications, which raises the risk of drug interactions. Kidney or liver function may be reduced, making it harder to clear antibiotics. And neurological symptoms from Lyme can increase the risk of falls, which can have devastating consequences in this age group. Standard guidelines don’t always address these realities. What works well for a younger patient may not be safe—or effective—for someone in their eighties. That’s why Lyme disease treatment in elderly patients requires individualized care. Every decision has to balance infection control with age-related vulnerabilities. Antibiotics may be necessary, but they can also increase risks like dehydration, C. difficile infection, or secondary complications. Medications for neuropathy may relieve pain but could also cause sedation and falls. And we can’t overlook the role of co-infections like Babesia or Bartonella, which make recovery even more complicated. As an ILADS guideline author, I’ve emphasized the importance of clinical judgment and patient-centered care. For elderly patients, that means more frequent monitoring, lower starting doses, and close coordination with family and caregivers. The goal isn’t just to fight infection—it’s to preserve function, independence, and quality of life. So here’s the bottom line: elderly Lyme disease patients need more than standard protocols. They need individualized care that takes into account the whole person, not just the infection.”

“Has your family faced challenges with Lyme disease treatment for kids? Share your story in the comments—because until children are included in research, parents’ voices are one of the most powerful tools we have. . . No NIH-funded Lyme treatment trials have included children under 18. Yet kids often present differently than adults—showing fatigue, mood or school changes, rather than joint pain. Their developing immune and nervous systems also process infection and medication uniquely. Because guidelines rely on adult data, children risk being dismissed or undertreated. Some relapse if therapy ends too soon, while others improve only when co-infections are addressed. Bottom line: pediatric Lyme requires individualized, flexible care until research finally includes children. . . #LymeDisease #LymeTreatment #PediatricLyme #LymeAwareness #ChildHealth #LymeWarrior #ChronicLyme #InvisibleIllness #ParentVoices

Have you experienced gaslighting in your Lyme journey? Drop your story below—your voice can help others feel less alone. . . Summary Many Lyme disease patients experience medical gaslighting—dismissive comments like “your labs are normal” or “the treatment is finished”—even while symptoms like fatigue, brain fog, pain, and neuropathy persist. This erodes trust, adds psychological harm, and often drives patients toward alternative medicine, not out of rejection of science but in search of time, holistic care, ongoing support, and validation. The solution isn’t to push patients away, but to listen, explain uncertainties, stay connected, and collaborate when integrative care is sought. At its core, Lyme patient gaslighting is both a medical and ethical failure. Patients deserve to be believed and supported.

I’m Dr. Daniel Cameron. In my practice, I often see patients with chronic pain, and I want to explore whether chronic Lyme disease could be part of the puzzle behind America’s growing pain epidemic. A recent paper by Jovkovich in Pain reported that chronic pain prevalence in U.S. adults rose from 21% in 2019 to 24% in 2023—affecting 60 million people. Only about 13% of this increase was linked to long COVID. The rest remains unexplained. Overlap Between Lyme Pain and National Pain Trends The types of pain described—back, neck, joint, headache, abdominal, and widespread musculoskeletal pain—mirror what I see in chronic Lyme patients. Lyme pain is often multi-system, migratory, unpredictable, and can flare with fatigue and stress. It includes: Musculoskeletal pain: Joint and tendon pain, often misdiagnosed as fibromyalgia. Neurologic pain: Headaches resistant to migraine therapy, burning or electrical-shock sensations, small fiber neuropathy. Abdominal/pelvic pain: Frequently linked with autonomic dysfunction. Why Lyme Gets Missed Testing limitations: Standard CDC two-tier testing is more reliable in acute cases, leaving many chronic patients without positive results. Mislabels: Fibromyalgia, chronic fatigue syndrome, or “pain of unknown origin.” COVID-era factors: More outdoor exposure, missed diagnoses due to care delays, absent rash or visible tick bite. Geography and Demographics The pain hotspots in the Pain study—Northeast, Upper Midwest, Pacific coast—are also Lyme-endemic regions. Affected populations included working adults, outdoor enthusiasts, rural and suburban residents, aligning closely with Lyme risk groups. Strongest Evidence: Treatment Response Perhaps the clearest sign is clinical: when patients with undiagnosed Lyme receive targeted antibiotic or co-infection therapy, their chronic pain often improves or resolves. Bottom line: Chronic Lyme disease may be an overlooked contributor to America’s pain crisis. The symptoms overlap, the geography matches, and patients often respond to treatment. To better address the 60 million Americans in pain, we need to update diagnostic strategies, look beyond tick rash and positive tests, and include Lyme disease in the differential.

Welcome. Here are ten practical tips for Healthcare Providers to prevent chronic Lyme disease. 1. Lyme Disease is Primarily a Clinical Diagnosis • While laboratory tests, like the two-tiered approach of ELISA followed by Western blot, can provide valuable support, Lyme disease diagnosis hinges on clinical judgment. The disease’s early symptoms, such as the classic erythema migrans rash, fever, and joint pain, often present before the immune system has generated detectable antibodies. This means that the diagnosis is often made based on clinical presentation, particularly in endemic areas, even if tests are negative. 2. Early Treatment Can Prevent Complications • The importance of early treatment in Lyme disease cannot be overstated. Studies have consistently shown that when antibiotics are administered promptly—ideally within weeks of infection—they can prevent the progression to more serious complications, such as Lyme arthritis, neuroborreliosis, and Lyme carditis. The window for optimal intervention is narrow, making early recognition and treatment vital. 3. Co-Infections Are Common and Complicate the Picture • Ticks don’t just carry Borrelia burgdorferi; they can also transmit other pathogens like Babesia microti, Bartonella henselae, and Anaplasma phagocytophilum. These co-infections can lead to overlapping or more severe symptoms and may require different or additional treatments. Research indicates that co-infections are present in up to 30% of Lyme disease cases, which underscores the importance of considering a broad differential diagnosis when symptoms persist. 4. Lyme Disease Can Mimic a Range of Other Conditions • Known as "The Great Imitator," Lyme disease can present with symptoms that resemble those of multiple sclerosis, rheumatoid arthritis, fibromyalgia, or chronic fatigue syndrome. This mimicry can lead to misdiagnoses, delaying proper treatment. It’s crucial for healthcare providers to consider Lyme disease in their differential diagnosis, especially in patients with a history of tick exposure. 5. Seronegative Lyme Disease is a Real and Recognized Phenomenon • Not all patients with Lyme disease will test positive on standard serologic tests, especially in the early stages or if they have received early antibiotic treatment. This phenomenon, known as seronegative Lyme disease, can make diagnosis challenging. Clinical studies suggest that up to 20-30% of early Lyme disease cases may be seronegative, which requires healthcare providers to rely on their clinical instincts and patient history. 6. Post-Treatment Lyme Disease Syndrome (PTLDS) Requires Attention • PTLDS, affecting 10-20% of Lyme disease patients, presents a significant challenge. Symptoms like fatigue, pain, and cognitive difficulties persist long after the infection should have been cleared. The exact cause of PTLDS is still debated, with theories ranging from persistent infection to autoimmune dysfunction. What is clear, however, is that these patients need careful management and support, rather than dismissal. 7. Prevention Through Tick Avoidance is Key • Preventing tick bites is the most effective strategy to avoid Lyme disease and its associated complications. This includes the use of insect repellents, wearing protective clothing, performing regular tick checks, and removing ticks promptly. Education about these preventive measures is essential, particularly in areas where Lyme disease is endemic. 8. Rash is Not Always Present, but It’s a Strong Indicator 9. Lyme Disease is Expanding Beyond Traditional Regions 10. Lyme Disease Can Affect Multiple Organ Systems

I'm Dr. Daniel Cameron, and today I’m addressing a question I often see in my practice: What are the risk factors for chronic Lyme disease? Chronic Lyme Symptoms Some patients do not fully recover from Lyme disease. They experience a broad range of symptoms, including ongoing fatigue, pain, sleep problems, neurologic changes, emotional strain, and disruption of daily life. These challenges can affect school, parenting, and work responsibilities. Common chronic Lyme manifestations include: Musculoskeletal: chronic arthritis, muscle pain, stiffness, and tendon inflammation. Neurologic and psychiatric: brain fog, memory issues, neuropathy, sensory changes, depression, irritability, mood swings, and PANS. Post-treatment Lyme disease syndrome (PTLDS) is often debated, but I view it as a potential ongoing infection rather than simply a syndrome. Cardiovascular/dysautonomia: POTS, Lyme carditis, arrhythmias, chest pain, and dizziness. Other manifestations: sensory overload (light, sound, heat, cold, or smell sensitivity), sometimes related to dysautonomic issues. Risk Factors for Chronic Lyme Disease While formal assessments are ongoing, in my practice I see several consistent contributors: Severe initial infection such as neurologic Lyme meningitis or carditis. Treatment delays, sometimes months or years. Early systemic involvement at onset—widespread fatigue, pain, neurological symptoms, or functional loss. Co-infections such as Babesia and other tick-borne pathogens. Reinfections and relapses, which can increase the likelihood of chronic complications. Key Takeaways for Clinicians Screen patients carefully for these risk factors. Monitor for co-infections, especially in high-risk or relapsing patients. Do not dismiss persistent symptoms, even if a formal diagnosis has not yet been established. Advice for Patients Seek early treatment—timing matters. If symptoms persist, pursue a second opinion or find a physician experienced in managing chronic manifestations of Lyme disease. Watch for co-infections, especially Babesia, which may complicate recovery and even mimic other conditions (e.g., menopause). Advocate for comprehensive care for yourself and your family. Thank you for joining me. Please leave your questions and comments below—I read them all and respond where I can.

Lyme and PANS: A Critical Connection in Teenagers At just 16, my patient found herself facing a complex and overwhelming set of symptoms. What began as ordinary teenage stress evolved into something far more debilitating—raging outbursts, severe compulsions, motor and vocal tics, and memory problems. Her academic performance plummeted, and her social life disintegrated. Diagnosed with Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), she and her family embarked on a challenging journey for answers. PANS, a condition characterized by the sudden onset of severe neuropsychiatric symptoms, is often triggered by infections or autoimmune responses. These symptoms include obsessive-compulsive behaviors, severe anxiety, and a wide array of neurological issues. In my patient's case, the impact was profound, disrupting nearly every aspect of her life. A Frustrating Treatment Journey Her school quickly implemented a 504 plan to accommodate her needs, but even with these supports, she struggled to attend classes regularly. The academic gaps widened, and the isolation grew. Initially, her treatment focused on intravenous immunoglobulin (IVIG) therapy, a standard approach for PANS aimed at modulating the immune system. Unfortunately, despite several courses of IVIG, her symptoms persisted, leading to a sense of despair for both her and her family. The Lyme Disease Connection It wasn’t until the family explored further that they discovered a potential link between Lyme disease and PANS. Lyme disease, transmitted by ticks and caused by the Borrelia burgdorferi bacterium, is notorious for its wide range of symptoms, many of which can overlap with neuropsychiatric disorders. When Lyme disease enters the picture, it can trigger or exacerbate PANS, leading to an even more complicated clinical scenario. Upon testing, my patient was diagnosed with Lyme disease and a co-infection, which had gone undetected. The realization that these infections were contributing to her PANS symptoms was a breakthrough. She began antibiotic therapy, which is often essential in treating Lyme disease, especially when co-infections are involved. Over time, this approach started to pay off—her symptoms gradually improved, the rage outbursts and compulsions became less frequent, and her cognitive function began to recover.

Chronic Lyme disease, characterized by persistent symptoms that can linger for months or even years, is a growing concern for both patients and healthcare providers. Traditionally, Lyme disease has been seen as a straightforward infection—diagnosed early, treated with antibiotics, and resolved. However, for a significant number of people, Lyme disease can evolve into a chronic condition, marked by ongoing fatigue, pain, and cognitive issues. But what if much of this chronic suffering could be prevented? Recent insights suggest that the progression to chronic Lyme disease might be mitigated, or even prevented, by focusing on several key factors. This approach is similar to how we prevent other chronic diseases like type 2 diabetes or heart disease: through early detection and appropriate treatment. **The Importance of Early Diagnosis and Treatment** One of the most critical steps in preventing chronic Lyme disease is the early diagnosis and treatment of the infection. When a patient presents with a tick bite or early symptoms of Lyme disease, such as the characteristic erythema migrans rash, it’s vital to begin treatment promptly. Early intervention with antibiotics like doxycycline can significantly reduce the risk of the infection progressing to a chronic stage. Moreover, it’s essential to maintain a vigilant follow-up process. Even after initial treatment, patients should be asked to return for evaluation if symptoms persist or recur. Lyme disease can sometimes be insidious, with symptoms reappearing after what seems like successful treatment. Regular follow-ups allow healthcare providers to monitor the patient’s progress and catch any signs of relapse early. **Look for Co-Infections** Co-infections are another critical factor in the progression of Lyme disease to a chronic condition. Ticks often carry more than just Borrelia burgdorferi, the bacteria responsible for Lyme disease—they can also transmit other pathogens like Babesia, Bartonella, and Anaplasma. These co-infections can complicate the clinical picture and may require different treatments. It’s important to test for and consider co-infections, especially if a patient’s symptoms do not resolve with standard Lyme treatment. Addressing all possible infections early on can prevent the persistence and worsening of symptoms. **Consider Retreatment** In cases where initial treatment does not fully resolve the symptoms, it may be necessary to consider retreatment. Clinical judgment plays a crucial role here. While some cases of Lyme disease respond well to the standard course of antibiotics, others may require a more prolonged or alternative treatment approach. Retreatment should be considered for patients who continue to experience significant symptoms, particularly if they show signs of ongoing infection or co-infections. **Follow-Up Care is Crucial** Consistent follow-up care is essential in managing Lyme disease and preventing its progression to a chronic state. Even after symptoms appear to have resolved, patients should be monitored for any signs of recurrence or new symptoms. Chronic Lyme disease can sometimes develop months or even years after the initial infection, making long-term follow-up a key component of care. **Environmental Awareness and Preventive Measures** **Raising Awareness and Improving Access to Care**

The likely reason for relapse is failure to eradicate the spirochete completely with a two-week course of intravenous ceftriaxone therapy,” wrote Drs. Logigian, Kaplan, and Steere in their seminal 1990 paper on chronic neurologic Lyme disease. This observation remains as relevant today as it was over three decades ago, highlighting a persistent challenge in the treatment of Lyme disease: the difficulty in fully eliminating the Borrelia burgdorferi bacterium, which can lead to relapse or persistent symptoms even after what is considered adequate treatment. In chronic Lyme disease, or what is often referred to as Post-Treatment Lyme Disease Syndrome (PTLDS), patients continue to suffer from symptoms such as fatigue, pain, and cognitive difficulties long after completing the standard antibiotic courses. This condition has sparked considerable debate within the medical community. Some experts believe that ongoing symptoms are due to lingering effects of the initial infection, while others propose that they may be due to an active, persistent infection that was not fully eradicated by the initial treatment. The 1990 study by Logigian, Kaplan, and Steere explored these possibilities by examining patients who had been treated with a two-week course of intravenous ceftriaxone. Despite this treatment, some patients either relapsed or failed to recover fully, leading the authors to speculate that the spirochete might not have been completely eradicated. This concept has been supported by subsequent studies suggesting that Borrelia burgdorferi can persist in the body in a dormant state, possibly shielded within tissues where antibiotics have limited penetration. More recent research has further explored the idea of persistent infection. Studies have shown that Borrelia burgdorferi can form biofilms—complex communities of bacteria that are more resistant to antibiotics. These biofilms could potentially harbor bacteria that re-emerge after the initial course of antibiotics is completed, leading to the recurrence of symptoms. Moreover, the nature of Lyme disease itself complicates treatment. The bacterium Borrelia burgdorferi can exist in multiple forms—spirochete, round-body, and biofilm—which might require different antibiotics or treatment approaches to fully eradicate. This complexity may explain why some patients do not respond to the standard treatment regimen. For patients like mine, who experience a relapse after standard treatment, the journey can be frustrating and disheartening. The initial hope of recovery is replaced by confusion and concern when symptoms return or persist. This situation emphasizes the need for ongoing research into more effective treatment strategies for chronic Lyme disease, including longer antibiotic courses, combination therapies, and alternative treatments that address the different forms the bacterium can take. The challenge of treating chronic Lyme disease also raises important questions about the broader healthcare system’s approach to this condition. There is a pressing need for more awareness among healthcare providers, more research funding to explore the underlying mechanisms of persistent infection, and better support systems for patients navigating the complexities of this illness. In conclusion, the issue of relapse in Lyme disease treatment is not just a clinical problem but also a deeply personal one for patients who struggle to regain their health. It highlights the importance of individualized treatment approaches, ongoing patient support, and the continuous pursuit of knowledge to develop more effective treatments for this complex and often misunderstood disease.

My patient recovered from her chronic illness after receiving early aggressive treatment, a result that underscores the importance of this approach in managing Lyme disease. Chronic illness resulting from Lyme disease is one of the most compelling reasons I advocate for early aggressive treatment. Lyme disease is not just a simple infection; if left inadequately treated, it can lead to a range of severe and persistent conditions. Chronic neurologic Lyme disease can cause debilitating symptoms such as cognitive impairments, severe headaches, and neuropathy. POTS (Postural Orthostatic Tachycardia Syndrome) and PANS (Pediatric Acute-onset Neuropsychiatric Syndrome) are other serious complications that can significantly disrupt a patient’s life, leading to symptoms like dizziness, rapid heart rate, and sudden behavioral changes. Lyme arthritis, another potential outcome, can cause long-term joint pain and swelling, making daily activities difficult. Lyme carditis, which affects the heart, can lead to dangerous complications, including heart block and arrhythmias. Neuropsychiatric Lyme, involving mood disorders, anxiety, and cognitive dysfunction, adds an additional layer of complexity to the patient’s condition, affecting mental health and overall quality of life. Given the high stakes, early aggressive treatment becomes not just an option but a necessity. By intervening quickly and with a comprehensive treatment plan, we can reduce the risk of these chronic manifestations taking hold. In my experience, starting treatment early—often before the full spectrum of symptoms has developed—can make a significant difference in the patient’s prognosis. This approach also involves treating potential co-infections like Babesia and Bartonella from the outset, even if they haven’t been fully confirmed. These co-infections can complicate the clinical picture and contribute to the persistence of symptoms if not addressed early. By being proactive and thorough, we can give patients the best chance of a full recovery and prevent the long-term complications that make Lyme disease so challenging. Ultimately, early aggressive treatment is about more than just addressing an infection; it’s about preventing the transition from an acute illness to a chronic, life-altering condition. It’s about giving patients the opportunity to regain their health and quality of life as quickly as possible, without the lingering fear of ongoing or worsening symptoms. The success of this approach with my patients reinforces its importance and validates the need for a proactive, comprehensive strategy in treating Lyme disease.

When I first began treating Lyme disease, I adopted an “escalation” approach. This method involved starting with a standard course of doxycycline, typically lasting a month, and then observing how the patient responded. If the symptoms persisted or if I suspected that a co-infection might be present, I would escalate the treatment—adding or changing medications as needed. This approach was cautious and reactive, focusing on adjusting the treatment plan based on the patient’s progress over time. However, through years of experience and patient outcomes, I’ve shifted my strategy to what I now call an “early aggressive” treatment approach. Rather than waiting to see if symptoms persist or worsen, I take proactive steps right from the start. If I suspect a co-infection with Babesia, I start treatment with atovaquone right away. This is crucial because Babesia requires different treatment than Lyme disease and can significantly impact recovery if not addressed early. Similarly, if Bartonella is a possibility, I begin treatment early, even if I’m not sure of the exact source. Similarly, if I suspect Bartonella, another common co-infection, I begin treatment early, even if I haven’t confirmed whether the infection was transmitted by a tick or a cat. Bartonella can cause a range of symptoms that complicate Lyme disease, and early intervention can prevent the condition from becoming more severe or chronic. This “early aggressive” approach represents a significant shift from the more traditional, wait-and-see methods. The reasoning behind this shift is rooted in the understanding that Lyme disease and its co-infections can be relentless and complex, with symptoms that vary widely among patients. By addressing potential complications head-on and without delay, I’ve seen much better patient outcomes. Recovery times are often shorter, and the risk of developing chronic symptoms is reduced. Moreover, this approach is not just about quicker recovery—it’s also about improving the overall patient experience. Lyme disease can be a devastating condition, both physically and emotionally. The uncertainty and frustration that come with prolonged illness can take a significant toll on a patient’s mental health and quality of life. By being proactive and addressing all possible aspects of the disease early, I can provide my patients with a clearer path to recovery and reduce the likelihood of prolonged suffering. In summary, my move to an “early aggressive” treatment strategy has been shaped by my commitment to providing the best possible care for my patients. This approach allows me to tackle Lyme disease and its co-infections more effectively, offering patients a better chance at a swift and complete recovery. It’s about being proactive, thorough, and responsive to the complex nature of tick-borne illnesses, ensuring that no stone is left unturned in the quest to restore my patients’ health.

In this episode, Dr. Cameron will be discussing the case of a 64-year-old woman with central nervous system involvement of the brain. The case was first described by Mullholand and colleagues in the British Medical Journal in a paper entitled “Central nervous system involvement of anaplasmosis.” 1 A 64-year-old woman was hospitalized with a 24-hour history of confusion and lethargy. The following morning, her lethargy had worsened and she developed subjective fever, mild headache, nausea, vomiting and increased confusion, according to the authors.

Dr. Daniel Cameron. In this episode, Dr. Cameron will be discussing the case of a 63-year-old woman who was diagnosed with Southern Tick-Associated Rash Illness (STARI). The authors discuss the differences and similarities of STARI and Lyme disease: In their article “Southern Tick-Associated Rash Illness: Florida’s Lyme Disease” Abdelmaseih and colleagues describe the woman’s case, highlighting the differences between STARI and Lyme disease.¹ You can hear more about these cases through his blogs, social media, and YouTube. Sign up for our newsletter to keep up with these cases. How to Connect with Dr. Daniel Cameron: https://www.DanielCameronMD.com/DCameron@DanielCameronMD.comhttps://danielcameronmd.com/contact-daniel-cameron-md/https://www.instagram.com/drdanielcameron/https://www.facebook.com/danielcameronmd/https://twitter.com/DrDanielCameronhttps://www.DanielCameronMD.com/https://www.youtube.com/user/danielcameronmd/We, of course, hope you’ll join the conversation, connect with us and other readers, ask questions, and share your insights. Dr. Cameron is a Lyme disease expert and the author "Inside Lyme: An expert's guide to the science of Lyme disease." He has been treating adolescents and adults for more than 30 years. Please remember that the advice given is general and not intended as specific advice as to any particular patient. If you require specific advice, then please seek that advice from an experienced professional.